Evidence map›Paper›PMID 39175975›Full record

ArticleOpen veterinary journal2024

Prophylactic impacts of

Najlaa H Almohmadi, Mona Zahran, Sameh M El-Nabtity, Hazem M Shaheen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open veterinary journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Najlaa H AlmohmadiClinical Nutrition Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia.
Mona ZahranPharmacology Department, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt.
Sameh M El-NabtityPharmacology Department, Faculty of Veterinary Medicine, Zagazig University, Zagazig, Egypt.
Hazem M ShaheenDepartment of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Doxorubicin (DOX) is a chemotherapeutic drug applied clinically for the remedy of cancer, but its possibly life-threatening cardiotoxicity effects remain a concern. Aim: After that, this study evaluates the cardioprotective impacts of Methods: Wistar male rats ( Results: Results revealed no significant change in CK-MB levels between the DOLS group compared to the CTR group ( Conclusion: This study highlights the favorable impacts of LSS oil in mitigating DOX-triggered cardiotoxicity in a rat model.

Indexed as

CardiomyopathiesDoxorubicinRats, WistarAnimalsAntibiotics, AntineoplasticCardiotoxicityCucurbitaceaeMalePlant ExtractsPlant OilsRatsAntibiotics, AntineoplasticDoxorubicinPlant ExtractsPlant OilsAntioxidant activityCardiotoxicityDoxorubicinLagenaria sicerariaRat

Identifiers

PMID39175975
PMCPMC11338615

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.